PMID- 30755240 OWN - NLM STAT- MEDLINE DCOM- 20190528 LR - 20200225 IS - 1742-2094 (Electronic) IS - 1742-2094 (Linking) VI - 16 IP - 1 DP - 2019 Feb 12 TI - Correlation of alteration of HLA-F expression and clinical characterization in 593 brain glioma samples. PG - 33 LID - 10.1186/s12974-019-1418-3 [doi] LID - 33 AB - BACKGROUND: Human gliomas are highly fatal tumors with a significant feature of immune suppression. The association of the immune system in gliomas is gradually revealed, and immunotherapy is expected to improve the survival of glioma patients. In-depth understanding of the immune microenvironment of gliomas and their associated immunotherapy was increased exponentially in recent years. Gliomas provide clinical targets for immunotherapy during the search of key regulators of immune response. Our study focused on the human leukocyte antigen (HLA) system that is responsible for regulating the immune system, and discovered the relationship between HLA-F expression and clinical prognosis in gliomas. METHODS: A total of 593 patients with gliomas were included in our research. Of these, 325 patients were from the Chinese Glioma Genome Atlas (CGGA) and 268 were from the GSE 16011 set. Kaplan-Meier (KM) analysis was performed to explore the prognostic value of HLA-F. t test analysis was used to find the distribution difference in various groups. R language packages are used for other statistical computations and figure drawing. RESULTS: HLA-F was negatively correlated with overall survival (OS) in all grades of glioma and glioblastoma (GBM). Moreover, HLA-F was enriched in GBM and isocitrate dehydrogenase 1 wild-type (IDH1 wt) group and considered HLA-F as a mesenchymal subtype marker. Pearson correlation test showed that HLA-F was correlated with other HLA-I molecules. CONCLUSION: HLA-F expression was positively correlated with malignant phenotype and negatively correlated with OS, indicating that HLA-F could predict the immune state of gliomas and might be a clinical target of glioma immunotherapy. FAU - Feng, Enshan AU - Feng E AD - Department of Neurosurgery, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. enshanfeng@126.com. FAU - Liang, Tingyu AU - Liang T AD - Department of Neurosurgery, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. FAU - Wang, Xiaoyong AU - Wang X AD - Department of Neurosurgery, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. FAU - Du, Juan AU - Du J AD - Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. FAU - Tang, Kai AU - Tang K AD - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantan Xili, Dongcheng District, Beijing, 100050, China. FAU - Wang, Xiaoxuan AU - Wang X AD - Capital Medical University, Beijing, 100069, China. FAU - Wang, Fang AU - Wang F AD - Department of Neurosurgery, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. FAU - You, Gan AU - You G AD - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantan Xili, Dongcheng District, Beijing, 100050, China. Ganyou2016@126.com. LA - eng GR - PX2018079/Beijing Medical Management Bureau Cultivation Plan/ GR - NO. 81871013/National Natural Science Foundation of China/ GR - YSP 201705/Beijing Tiantan Hospital Young Scientist Program/ PT - Journal Article DEP - 20190212 PL - England TA - J Neuroinflammation JT - Journal of neuroinflammation JID - 101222974 RN - 0 (HLA-F antigens) RN - 0 (Histocompatibility Antigens Class I) RN - 0 (RNA, Messenger) RN - EC 1.1.1.41 (Isocitrate Dehydrogenase) RN - EC 1.1.1.42. (IDH1 protein, human) SB - IM MH - Brain Neoplasms/genetics/*metabolism MH - False Positive Reactions MH - Female MH - Gene Expression Regulation, Neoplastic/*genetics MH - Gene Ontology MH - Glioma/genetics/*metabolism MH - Histocompatibility Antigens Class I/*genetics/*metabolism MH - Humans MH - Isocitrate Dehydrogenase/genetics MH - Male MH - Mutation/genetics MH - RNA, Messenger/metabolism MH - ROC Curve PMC - PMC6373026 OTO - NOTNLM OT - Glioma OT - HLA-F OT - Immunotherapy OT - OS COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: All the procedures in this study were approved by the ethics committees of all hospitals, and written informed consent was obtained from all patients. CONSENT FOR PUBLICATION: Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient/parent/guardian/relative of the patient. A copy of the consent form is available for review by the Editor of this journal. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2019/02/14 06:00 MHDA- 2019/05/29 06:00 PMCR- 2019/02/12 CRDT- 2019/02/14 06:00 PHST- 2018/08/18 00:00 [received] PHST- 2019/01/28 00:00 [accepted] PHST- 2019/02/14 06:00 [entrez] PHST- 2019/02/14 06:00 [pubmed] PHST- 2019/05/29 06:00 [medline] PHST- 2019/02/12 00:00 [pmc-release] AID - 10.1186/s12974-019-1418-3 [pii] AID - 1418 [pii] AID - 10.1186/s12974-019-1418-3 [doi] PST - epublish SO - J Neuroinflammation. 2019 Feb 12;16(1):33. doi: 10.1186/s12974-019-1418-3.